CHARACTERIZATION AND PURIFICATION OF A NOVEL ANTI-HIV FACTOR
Funder
National Health and Medical Research Council
Funding Amount
$170,810.00
Summary
We have identified biological evidence for a novel anti-HIV factor in a patient who has not progressed to HIV disease in 22 years. We have identified active forms in a solution, which confer potent activity against HIV. This factor helps in creating the pool of specialized antigen presenting cells, which are vital to combating with HIV in vivo. We propose to characterize this factor biologically, proteomically and genomically.
Development Of The Quick Clinical On-line Evidence Based Decision Support System
Funder
National Health and Medical Research Council
Funding Amount
$124,500.00
Summary
Web information retrieval is of increasing importance to health professions. Yet, despite advances in technology, clinicians still have large unmet information needs with significant consequences for the public. QuickClinical is an evidence delivery system that utilises intelligent search filter technology to assist typical clinical tasks like ‘diagnosis’, ensuring only the most relevant evidence is retrieved. This grant will allow a research prototype to be taken to early commercialisation stag ....Web information retrieval is of increasing importance to health professions. Yet, despite advances in technology, clinicians still have large unmet information needs with significant consequences for the public. QuickClinical is an evidence delivery system that utilises intelligent search filter technology to assist typical clinical tasks like ‘diagnosis’, ensuring only the most relevant evidence is retrieved. This grant will allow a research prototype to be taken to early commercialisation stage, ready to be deployed in different environments for different clinical users.Read moreRead less
Novel Vaccine Formulation For Immunotherapy Of Adenocarcinomas
Funder
National Health and Medical Research Council
Funding Amount
$178,400.00
Summary
We have designed a vaccine based on a unique delivery system. Mice immunised with vaccine were protected from a tumour challenge. We will now design a vacine with a cancer associated protein so that people once immunised can make killer cells. Since humans have different genetic makeup we will produce a vacine which is more effective and will benefit everyone. This vaccine will be more effective than a current vacine in that has yielded promising results in humans.